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Background. The induction of tumor angiogenesis, a pathologic process critical for tumor progression, is mediated by
multiple regulatory factors released by tumor and host cells. We investigated the role of the hematopoietic cytokine
erythropoietin as an angiogenic factor that modulates tumor progression. Methodology/Principal Findings. Fluorescently-
labeled rodent mammary carcinoma cells were injected into dorsal skin-fold window chambers in mice, an angiogenesis model
that allows direct, non-invasive, serial visualization and real-time assessment of tumor cells and neovascularization
simultaneously using intravital microscopy and computerized image analysis during the initial stages of tumorigenesis.
Erythropoietin or its antagonist proteins were co-injected with tumor cells into window chambers. In vivo growth of cells
engineered to stably express a constitutively active erythropoietin receptor EPOR-R129C or the erythropoietin antagonist
R103A-EPO were analyzed in window chambers and in the mammary fat pads of athymic nude mice. Co-injection of
erythropoietin with tumor cells or expression of EPOR-R129C in tumor cells significantly stimulated tumor neovascularization
and growth in window chambers. Co-injection of erythropoietin antagonist proteins (soluble EPOR or anti-EPO antibody) with
tumor cells or stable expression of antagonist R103A-EPO protein secreted from tumor cells inhibited angiogenesis and
impaired tumor growth. In orthotopic tumor xenograft studies, EPOR-R129C expression significantly promoted tumor growth
associated with increased expression of Ki67 proliferation antigen, enhanced microvessel density, decreased tumor hypoxia,
and increased phosphorylation of extracellular-regulated kinases ERK1/2. R103A-EPO antagonist expression in mammary
carcinoma cells was associated with near-complete disruption of primary tumor formation in the mammary fat pad.
Conclusions/Significance. These data indicate that erythropoietin is an important angiogenic factor that regulates the
induction of tumor cell-induced neovascularization and growth during the initial stages of tumorigenesis. The suppression of
tumor angiogenesis and progression by erythropoietin blockade suggests that erythropoietin may constitute a potential
target for the therapeutic modulation of angiogenesis in cancer.
Citation: Hardee ME, Cao Y, Fu P, Jiang X, Zhao Y, et al (2007) Erythropoietin Blockade Inhibits the Induction of Tumor Angiogenesis and
Progression. PLoS ONE 2(6): e549. doi:10.1371/journal.pone.0000549
INTRODUCTION
Cancer progression is influenced by multiple factors including the
induction of tumor angiogenesis. Understanding tumor vascular-
ization and growth at its early stages can provide new insights into
mechanisms relevant to progression and metastasis, and facilitate
the development of novel anti-angiogenic therapies. We have been
interested in events that follow immediately after tumor cells are
triggered to initiate angiogenesis. Our previous studies provided
evidence that angiogenesis induced by tumor cells after implan-
tation in the host begins at a very early stage when the tumor mass
contains only 100 to 300 cells [1–5]. The induction of tumor
angiogenesis is mediated by many regulatory molecules released
by tumor and/or host cells and that constitute potential targets of
anti-angiogenic therapy. Vascular endothelial growth factor
(VEGF), an important regulator of both physiologic and patho-
logic angiogenesis, has been successfully targeted in pre-clinical
tumor models as well as in clinical trials involving cancer patients.
However, the benefits of anti-angiogenic therapy can be limited by
redundant mechanisms of angiogenesis control, a problem that
may potentially be overcome by targeting multiple angiogenic
pathways or the use of broad spectrum angiogenic inhibitors [6].
The characterization of novel angiogenic factors and potential
targets involved in the induction of tumor vascularization could
contribute to the development of more efficacious anti-angiogenic
therapeutic approaches.
Erythropoietin (EPO) is the hematopoietic cytokine that
regulates the formation of red blood cells by binding to the
erythropoietin receptor (EPOR), a member of the cytokine
receptor family that is expressed not only in erythroid cells, but
also in many non-hematopoietic cell types including vascular
endothelial cells and cancer cells [7]. The findings of recent clinical
trials reporting that recombinant erythropoietin (rEPO) therapy in
some cancer patients may negatively impact recurrence-free
survival have raised concerns regarding potential adverse direct
effects of erythropoietin in tumors, such as stimulation of the
proliferation of cancer cells and/or tumor angiogenesis [8–11].
Several preclinical studies have reported direct effects of rEPO on
cancer cells- such as activation of intracellular signal transduction
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have found no significant effects of EPO-EPOR on cancer cell
proliferation [7,12–15]. In vascular endothelial cells, EPOR
expression has been associated with the ability of EPO to stimulate
intracellular signaling and to promote angiogenic responses in
various experimental models [16–18]. EPO has been implicated in
the physiologic angiogenesis that occurs in the developing mouse
embryo [19], the female genital tract [20], and during wound
healing [21]. A more recent study reported that EPO is involved in
the pathologic angiogenesis of proliferative diabetic retinopathy
[22]. Although a role for EPO in tumor angiogenesis has been
suggested [23–26], its potential as a target and direct modulator of
pathologic tumor neovascularization is not established.
In the present study, we investigated the role of EPO in tumor
angiogenesis and progression. As an angiogenesis model, we used
fluorescently-labeled mammary carcinoma cells implanted in
dorsal skin-fold window chambers, a model that allows non-
invasive, direct, and serial visualization and assessment of both
tumor cells and pathologic neovascularization simultaneously.
This model has been used to evaluate angiogenic factors such as
VEGF, angiopoietin-2, basic fibroblast growth factor and
candidate angiogenesis inhibitors that target tumor vasculature
[1,2,5,27]. The in vivo growth of mammary carcinoma cells was
also assessed in mammary fat pad xenografts in athymic nude
mice. We find that local rEPO treatment in window chambers or
stable expression of a constitutively active EPOR mutant (EPOR-
R129C) in tumor cells promotes the induction of tumor
angiogenesis and stimulates growth. Conversely, targeting endog-
enous EPO using recombinant soluble EPOR (sEPOR) or
a neutralizing anti-EPO monoclonal antibody co-injected into
window chambers with mammary carcinoma cells inhibits the
initiation of tumor angiogenesis and delays growth during the
initial stages of tumorigenesis. In orthotopic tumor xenograft
studies, EPOR-R129C expression significantly promotes tumor
growth associated with increased expression of Ki67 proliferation
antigen, enhanced microvessel density, decreased tumor hypoxia,
and increased phosphorylation of the p44/42 extracellular-
regulated kinases ERK1/2. Stable expression in tumor cells of
a secreted EPO antagonist protein (R103A-EPO) exerts a remark-
able anti-angiogenic effect and impairs primary tumor growth
both in window chambers and in the mammary fat pad. These
data provide evidence that EPO is an important angiogenic factor
that modulates the induction of tumor cell-induced angiogenesis
and progression during the initial stages of tumor formation.
Suppression of tumor angiogenesis and growth by EPO blockade
suggests that EPO may constitute a potential target for the
therapeutic modulation of angiogenesis in cancer that warrants
further investigation.
RESULTS
Erythropoietin treatment in window chambers
promotes tumor angiogenesis and growth
Fluorescently-labeled R3230-GFP mammary carcinoma cells were
co-injected with erythropoietin into window chambers. Tumor
growth and neovascularization were assessed serially using
intravital microscopy. Representative fluorescent and transmitted
light images of the window chambers are illustrated (figure 1A, B).
Quantification of tumor neovascularization revealed significant
stimulation of angiogenesis in erythropoietin-treated window
chambers compared to buffer-treated negative controls
(figure 1C, table 1). The vascular length density increased by
78% compared to buffer-treated controls as early as day 2 after
tumor cell injection (P,0.001). Quantification of two-dimensional
tumor growth in window chambers revealed that the proangio-
genic effect of erythropoietin was associated with a significant
increase in tumor growth by 66% and 42% on days 2 and 4,
respectively, compared to controls (P,0.001, figure 1D, table 2).
The pro-angiogenic and growth promoting effects diminished with
time but remained significant by day 8. There was no significant
systemic effect of local erythropoietin administration in the
window chambers on the hematocrit levels of the animals
Figure 1. Stimulation of tumor angiogenesis and growth in response
to rEPO treatment. Representative images of dorsal skin-fold window
chambers implanted with R3230-GFP cells and local administration of
(A) control buffer, or (B) recombinant EPO are shown (total n=8
animals/group). Fluorescent (FITC) and transmitted light images were
acquired serially on postoperative days 2, 4, 6, and 8. Scale
bar=2.5 mm. GFP-positive tumor area (green fluorescence) is indicated
by white arrows and tumor-associated vasculature in transmitted light
images is outlined by black arrowheads. (C) Quantification of tumor
neovascularization as measured by vascular length density (VLD) in
window chambers treated with EPO or control buffer revealed
increased angiogenesis in EPO-treated chambers compared to controls,
*P,0.001. (D) Quantification of tumor growth revealed significantly
increased tumor area in EPO-treated chambers compared to controls,
*P,0.001; ** P,0.01.
doi:10.1371/journal.pone.0000549.g001
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controls).
Expression of constitutively active EPOR-R129C in
mammary carcinoma cells is associated with
increased angiogenic response and tumor growth
To further investigate the role of erythropoietin and its receptor in
tumor angiogenesis and progression, R3230-GFP cells were
engineered to express constitutively active EPOR-R129C, a mu-
tant EPOR that confers growth factor-independent proliferation
and tumorigenicity when expressed in immortalized hematopoietic
cells but does not transform normal fibroblasts [28–31]. Single cell
clones of R3230-GFP cells expressing EPOR-R129C were isolated
(figure S1) and in vitro growth rates and cell cycle profile of the
cells were characterized. R3230-GFP cells expressing EPOR-
R129C exhibited similar growth characteristics in serum-contain-
ing medium compared to vector-transfected negative control cells
(figure S1). When implanted into window chambers and
monitored serially by fluorescent and transmitted light intravital
microscopy, EPOR-R129C expression was associated with
a significant enhancement of tumor-cell induced neovasculariza-
tion and growth in all chambers (figure 2A, B). There was
a significant increase in vascular length density by 76% and 48%
on days 2 and 4, respectively, compared to controls (P,0.001,
figure 2C, table 1). This proangiogenic effect was associated with
a significant increase in tumor growth by 63% and 79% at day 6
and day 8, respectively (P,0.001, figure 2D, table 2).
To further characterize the in vivo growth of R3230-GFP cells
expressing EPOR-R129C, orthotopic tumor xenograft experi-
ments were performed by injecting the mammary carcinoma cells
into the mammary fat pad of athymic nude mice. Three
independent single cell clones of each stably transfected cell line
were analyzed and empty pCR3.1 vector-transfected cells served
as negative controls. Tumor growth rate was significantly
increased in animals injected with cells expressing EPOR-
R129C compared to the growth rate in animals injected with
negative control cells (P,0.001, figure 3, table 3).
Erythropoietin blockade using recombinant soluble
EPOR and anti-EPO monoclonal antibody inhibits
tumor angiogenesis and delays growth in window
chambers
We investigated whether protein inhibitors targeting EPO function
could suppress tumor-cell induced neovascularization and delay
growth. The antagonists recombinant sEPOR and neutralizing
monoclonal anti-EPO antibody (mab) inhibit EPO-dependent
proliferation of hematopoietic 32D cells that express the EPOR
(figure S2). We determined the in vivo effect of the antagonist
proteins on angiogenesis and tumor growth in window chambers.
Local, one-time treatment with the antagonist proteins, co-injected
with R3230-GFP tumor cells into window chambers, resulted in
significant inhibition of neovascularization and tumor growth
delay (figure 4A, B, C). The negative controls were treated with
mouse IgG1 (4 windows) or phosphate-buffered saline (3 windows).
Compared to controls, significant inhibition of tumor angiogenesis
was observed leading to decreased vascular length density by 44%
(sEPOR) and 47% (mab) at day 8 (P,0.001, figure 4D, table 1).
This anti-angiogenic effect was associated with significant tumor
growth delay with decreased two-dimensional tumor size by 37%
(sEPOR) and 39% (mab) at day 8 (P,0.001, figure 4E, table 2).
R103A-EPO antagonist secretion from mammary
carcinoma cells blocks induction of tumor
neovascularization and inhibits tumorigenesis
To target erythropoietin using a different strategy, R3230-GFP
cells were engineered to constitutively express and secrete mutant
erythropoietin protein R103A-EPO (figure S3). R103A-EPO is an
Table 1. Vascular length density measurements in window chambers (mm/mm
2).
..................................................................................................................................................
Time
Recombinant EPO EPOR-R129C
a Soluble EPOR and anti-EPO mab R103A-EPO
b
Buffer n=8 rEPO n=8 Vector n=7 R129C n=7 Control n=7 sEPOR n=7 mab n=7 Vector n=7 R103A n=7
Day 2 5.1860.2 9.2660.1 4.7460.1 8.3560.2 4.7260.1 3.5760.3 3.3460.2 5.9660.2 3.7560.1
Day 4 8.5460.4 12.5660.2 8.9460.2 13.2860.2 8.6760.9 5.860.2 5.6560.3 11.160.3 5.5860.2
Day 6 10.9660.2 14.9960.3 12.5860.2 14.6760.2 12.3460.7 7.4160.3 6.6460.3 13.6260.4 6.8160.2
Day 8 13.9660.2 15.9260.2 14.9260.2 16.3760.2 14.7260.4 8.6760.5 7.260.5 16.0360.4 7.9860.3
aTwo independent clones each of vector (pCR3.1) and EPOR-R129C transfected cells were used (3+4=7 animals/group).
bTwo independent clones each of vector (pCDNA3.1) and R103A-EPO transfected cells were used (3+4=7 animals/group).
doi:10.1371/journal.pone.0000549.t001
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Table 2. Tumor area measurements in window chambers (mm
2).
..................................................................................................................................................
Time
Recombinant EPO EPOR-R129C
a Soluble EPOR and anti-EPO mab R103A-EPO
b
Buffer n=8 rEPO n=8 Vector n=7 R129C n=7 Control n=7 sEPOR n=7 mab n=7 Vector n=7 R103A n=7
Day 2 1.4760.06 2.4560.21 1.5160.11 2.1460.26 2.0160.07 1.5460.13 1.8460.12 1.4360.14 0.8160.03
Day 4 2.4460.2 3.4860.09 2.1960.15 3.2060.34 360.1 3.0660.27 2.8160.22 2.4960.13 0.7960.05
Day 6 3.4260.07 4.2460.08 2.7360.14 4.4760.34 4.4760.26 3.3960.24 3.4560.34 3.4460.3 0.73.60.07
Day 8 4.36.60.14 560.05 3.1260.13 5.5860.31 5.5960.21 3.3660.29 3.0660.25 4.3560.4 0.660.07
aTwo independent clones each of vector (pCR3.1) and EPOR-R129C transfected cells were used (3+4=7 animals/group).
bTwo independent clones each of vector (pCDNA3.1) and R103A-EPO-transfected cells were used (3+4=7 animals/group).
doi:10.1371/journal.pone.0000549.t002
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liferation of hematopoietic cells acting as a competitive inhibitor of
erythropoietin [32]. The in vitro growth rates and cell cycle profile
of R3230-GFP cells expressing R103A-EPO antagonist were
similar to vector-transfected negative control cells (figure S1). We
previously showed that rEPO treatment induces the phosphory-
lation of the extracellular-regulated kinases ERK1/2 in R3230
cells [33]. Expression of the antagonist R103A-EPO had no
significant effect on the ability of rEPO to induce the increased
phosphorylation of ERK1/2 in mammary carcinoma cells (figure
S3). To determine the in vivo effects of secreted R103A-EPO
antagonist, tumor cells expressing R103A-EPO were implanted
into window chambers and angiogenesis induction and tumor
growth were monitored. Compared to empty vector-transfected
cells, there was striking inhibition of tumor-cell induced angio-
genesis and disruption of tumor formation associated with R103A-
EPO antagonist expression (figure 5A, B). Vascular length density
was significantly inhibited by 50% as early as day 4, with the
significant anti-angiogenic effect maintained throughout 8 days of
observation and measurements (P,0.001, figure 5C, table 1).
There was severe constriction and tapering of the blood vessels in
Figure 2. Stimulation of tumor angiogenesis and growth in response
to tumor cell EPOR-R129C expression. Representative images of dorsal
skin-fold window chambers implanted with R3230-GFP cells transfected
with (A) empty pCR3.1 vector control, or (B) EPOR-R129C expression
vector are shown. Scale bar=2.5 mm. Two independent single cell
clones each of empty pCR3.1 vector and EPOR-R129C-transfected cells
were tested for a total of 7 animals in each group. (C) Quantification of
tumor neovascularization in window chambers implanted with EPOR-
R129C or empty vector-transfected R3230-GFP cells revealed signifi-
cantly increased VLD in EPOR-R129C expressing group compared to
vector controls, *P,0.001. (D) Quantification of tumor growth in
window chambers implanted with EPOR-R129C or vector transfected
R3230-GFP cells revealed increased tumor area in EPOR-R129C
expressing group compared to vector controls, *P,0.001; **P,0.01
(n=7 animals/group).
doi:10.1371/journal.pone.0000549.g002
Figure 3. In vivo tumor growth of R3230 mammary carcinoma cells in
the mammary fat pad of nude mice. Stably transfected R3230-GFP
cells were injected into the mammary fat pad of mice, tumor volumes
were measured and expressed as fold-increase of palpable tumor size at
day 7. Three independent single cell clones of each cell line were
analyzed and empty vector-transfected cells (pCR3.1 and pcDNA3.1)
served as negative controls. Expression of EPOR-R129C was associated
with a significant increase in tumor growth rate compared to pCR3.1
vector controls (*P,0.001, n=19 tumors in EPOR-R129C and n=16 in
pCR3.1 group). No significant tumor growth was observed in animals
injected with cells expressing R103A-EPO antagonist (n=14) compared
to pcDNA3.1 vector transfected cells (**P,0.001, n=15 tumors in
pcDNA3.1 group).
doi:10.1371/journal.pone.0000549.g003
Table 3. Tumor volume measurements in mammary fat pad
(mm
3).
......................................................................
Day
pCR3.1 vector
(n=16)
EPOR-R129C
(n=19)
pcDNA3.1 vector
(n=15)
R103A-EPO
(n=14)
7 33.769.1 43.666.3 18.964.7 14.767
10 52.5 613.8 73.369.6 21.865.2 18.268.7
13 65.1616.7 111.5612.5 28.866.4 21.2610.2
17 84.7621.3 155.1616.8* 43.167.2 25.6611.9
20 106.3625.9 192.8619.9* 56.368.4 24.6611**
24 131.2630.9 253.1618.7* 67.6610.8 23.6610.7**
27 179636.5 378.7626.9* 99.3614.5 24.1611.5**
32 247642.8 507.3624.9* 163.1630.5 25.2612.6**
*p,0.05 compared to pCR3.1 vector control.
**p,0.05 compared to pcDNA3.1 vector control.
doi:10.1371/journal.pone.0000549.t003
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PLoS ONE | www.plosone.org 4 June 2007 | Issue 6 | e549areas surrounding the tumor. Furthermore, this striking anti-
angiogenic effect was associated with disordered tumor growth
and significant growth inhibition by 85% on day 8 when near-
complete disappearance of the implanted tumor cells was observed
in all chambers (P,0.001, figure 5D, table 2). There was no
systemic effect of tumor cell R103A-EPO antagonist expression on
Figure 4. Erythropoietin blockade using soluble EPOR or anti-EPO
mab suppress tumor angiogenesis and delay growth. (A–C)
Representative images of window chambers implanted with R3230-
GFP cells co-injected with (A) control buffer or protein, (B) sEPOR, or (C)
anti-EPO mab. Fluorescent and transmitted light images were acquired
serially on postoperative days 2, 4, 6, and 8. Scale bar=2.5 mm. (D)
Quantification of tumor neovascularization revealed significantly de-
creased angiogenesis in sEPOR and mab-treated chambers compared
to controls. Control buffer was PBS (n=3) and control protein was
mouse IgG1 (n=4), *P,0.001; **P,0.01, (n=7 animals/group). (E)
Quantification of tumor growth revealed significantly decreased tumor
area in sEPOR and mab-treated chambers compared to controls,
*P,0.001;
{P,0.05, (n=7 animals/group).
doi:10.1371/journal.pone.0000549.g004
Figure 5. Expression of R103A-EPO antagonist inhibits induction of
tumor angiogenesis and disrupts primary tumor growth. Represen-
tative images of window chambers implanted with R3230-GFP cells
transfected with (A) empty pcDNA3.1 vector, or (B) R103A-EPO
antagonist expression vector. Note the constriction and near-complete
disappearance of blood vessels in the areas surrounding the tumor
which was observed in all window chambers injected with cells
expressing R103A-EPO. Two independent single cell clones each of
empty pcDNA3.1 vector or R103A-EPO-transfected cells were analyzed
for a total of 7 animals in each group. (C) Quantification of tumor
neovascularization revealed decreased angiogenesis in window cham-
bers implanted with R103A-EPO secreting cells compared to vector
controls, *P,0.001. (D) Quantification of tumor growth in window
chambers implanted with R103A-EPO or vector transfected R3230-GFP
cells. Compared to vector controls, decreased tumor area was observed
in R103A-EPO expressing group with near-complete disappearance of
tumor cells at day 8 in all chambers, *P,0.001 (n=7).
doi:10.1371/journal.pone.0000549.g005
EPO and Tumor Angiogenesis
PLoS ONE | www.plosone.org 5 June 2007 | Issue 6 | e549hematocrit levels of the animals (48.861.3% compared to
47.360.4 % in controls).
The in vivo growth of R3230-GFP cells expressing R103A-EPO
antagonist was further characterized in orthotopic tumor xeno-
graft experiments by inoculating the tumor cells in the mammary
fat pad of athymic nude mice. Three independent single cell clones
of the stably transfected cell lines were analyzed and empty
pCDNA3.1 vector-transfected cells served as negative controls. As
illustrated in Figure 3, primary tumor growth was severely
impaired in the animals injected with cells expressing R103A-
EPO, compared to the expected tumor growth in animals injected
with negative control cells (P,0.001, table 3).
Enhanced EPO-induced phosphorylation of ERK1/2
and c-Jun-NH2-kinase (JNK) in mammary carcinoma
cells expressing EPOR-R129C
We evaluated the activation of EPO-dependent signal trans-
duction in R3230 mammary carcinoma cells engineered to express
the constitutively active EPOR-R129C mutant. Hematopoietic
cells expressing EPOR-R129C have been reported to exhibit
constitutiveaswellasEPO-inducible phosphorylation and activation
of the cytoplasmic tyrosine kinase JAK2, its substrate STAT5 and
extracellular-regulated kinases ERK1/2 [34–37]. However, in
mammary carcinoma cells, we did not observe any significant
changes in the tyrosine phosphorylation of JAK2 in cells expressing
EPOR-R129C. Moreover, rEPO treatment failed to induce the
tyrosine phosphorylation of JAK2 or STAT5 in mammary
carcinoma cells (figure 6A), even following longer time-course
stimulation of the cells with rEPO (data not shown). Failure of rEPO
to induce the tyrosine phosphorylation of JAK2 or STAT5 was also
observed in human breast cancer cell lines MCF-7 and MDA-MB-
231 (data not shown). In a non-hematopoietic myoblast-like cell line,
EPO has been previously reported to induce the tyrosine
phosphorylation of JAK1 [38], however, rEPO did not induce the
tyrosine phosphorylation of JAK1 in mammary carcinoma cells
(figure 6A). We found that rEPO treatment induced the increased
phosphorylation of ERK1/2 and c-Jun-NH2-kinase (SAPK/JNK)
which were significantly enhanced in cells expressing EPOR-R129C
(figure 6B, C). Despite increased ERK1/2 and JNK phosphoryla-
tion, rEPO treatment of the cells did not result in consistent
stimulation of cell proliferation in vitro (data not shown).
Tumor cell EPOR-R129C expression is associated
with increased in vivo ERK1/2 phosphorylation, Ki67
proliferation antigen expression and microvessel
density
We then investigated whether EPOR-R129C expression may be
associated with increased in vivo phosphorylation of ERK1/2 in
mammary fat pad tumors by immunocytochemical staining.
Representative photomicrographs of empty vector and EPOR-
R129C tumors are shown (figure 7A, B). In EPOR-R129C
tumors, there was a significant increase in phospho-ERK1/2
positive tumor cells compared to vector controls (P,0.0001,
figure 7C). The presence of increased phospho-ERK in EPOR-
R129C tumors was associated with increased Ki67 proliferation
antigen expression (P=0.0006, figure 7D). Assessment of tumor
angiogenesis revealed a significant increase in microvessel density
in EPOR-R129C tumors compared to vector controls (P=0.0008,
figure 7E) and the increased microvessel density in EPOR-R129C
tumors was associated with significant decrease of tumor hypoxia
as determined by immunostaining for pimonidazole adduct
formation (P=0.026, figure 7F).
DISCUSSION
The present studies show that erythropoietin is an important
angiogenic factor that regulates the induction of tumor neovascu-
larization. A key aspect of our studies is the direct, serial and
simultaneous visualization and assessment of both implanted
tumor cells and host blood vessels to show that endogenous
erythropoietin is a critical factor involved in the attraction of new
capillaries to vascularize the expanding tumor mass. Using three
different inhibition strategies targeting endogenous EPO-EPOR -
including the administration of sEPOR and anti-EPO mab
proteins as well as tumor cell R103A-EPO antagonist expression-
the data demonstrates that erythropoietin blockade can effectively
inhibit the host angiogenic response and thereby severely impair
primary tumor growth. The magnitude of the anti-angiogenic and
anti-tumor effects of erythropoietin blockade using R103A-EPO
expression is comparable to that achieved by targeting VEGF in
window chambers in our previous experiments [2,5]. Thus, our
current findings suggest that the EPO-EPOR system may
constitute a potential target for the therapeutic modulation of
angiogenesis in cancer that warrants further investigation.
Here, we find that local rEPO administration induces
a significant proangiogenic effect and a transient stimulation of
tumor growth in window chambers. In previous studies,
systemically administered rEPO over a 3 to 4 week period did
not enhance the growth of various types of tumor xenografts,
including R3230 tumors, despite the ability of erythropoietin to
activate intracellular signaling in the cells [33,39,40]. It is possible
that the pro-angiogenic properties and modest growth-promoting
effects of EPO require sustained and high local concentrations in
the tumor microenvironment that cannot be achieved by systemic,
intermittent rEPO administration. To further investigate the role
of tumor cell EPOR expression, we over-expressed the constitu-
tively active EPOR-R129C in R3230 cells and found significantly
increased tumor growth rate in both window chambers and
orthotopic xenografts, demonstrating that EPOR over-expression
and signaling in mammary carcinoma cells is capable of
promoting growth. The over-expression of EPOR-R129C in
cancer cells was specifically associated with the increased
phosphorylation of ERK1/2 both in vitro and in vivo. In contrast
to the well-established signaling pathway activation mediated by
EPO-EPOR in hematopoietic cells, EPO treatment of mammary
carcinoma cells did not induce the phosphorylation of the JAK2/
STAT5 axis- a critical pathway for physiologic EPOR function in
hematopoietic cells [41]. These findings suggest the presence of
significant differences between EPOR-mediated signaling in
hematopoietic cells compared to tumor cells and that the level of
EPOR expression in tumor cells may modulate cellular responses
to exogenous EPO. Thus, the development of novel reagents and
techniques to accurately quantify EPOR expression in primary
human tumors is required as a tool to further characterize EPO
biology in cancer.
An important finding of our studies is that EPO blockade in
window chambers disrupted tumor neovascularization and
growth, particularly in the window chambers implanted with
R3230-GFP cells secreting the R103A-EPO antagonist which was
associated with virtual disappearance of tumor-associated blood
vessels, and eventually, the implanted tumor cells. Although the
window chamber angiogenesis model provides the advantage of
direct visualization of both tumor cells and host vasculature
simultaneously, it is limited by the requirement of growing tumors
in an ectopic site and the two-dimensional assessment of tumor
growth. Therefore, we examined the growth of mammary
carcinoma cells injected into the mammary fat pad and found
an even more dramatic effect of erythropoietin blockade in our
EPO and Tumor Angiogenesis
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in cancer cells almost completely abrogated primary in vivo tumor
formation. Suppression of in vivo tumor growth in window
chambers and in the orthotopic site occurred despite similar in
vitro proliferation rate of R103A-EPO expressing cells compared to
controls (figure S1). The remarkable anti-angiogenic effect
associated with R103A-EPO-secreting tumor cells in window
chambers and the disruption of tumor growth in the mammary fat
pad suggest the presence of a paracrine inhibitory effect of R103A-
EPO antagonist on the host neovascularization response. Taken
together, these findings are consistent with the dependence of
individual tumor cells on early angiogenic activity for both survival
and proliferation in vivo and provide evidence for the critical role
for endogenous EPO-EPOR in this process.
Our findings suggest that further investigation is warranted to
employ erythropoietin blockade for the therapeutic modulation of
tumor angiogenesis. The therapeutic efficacy of different inhibitors
of angiogenesis may vary depending on the stage of carcinogenesis
Figure 6. Increased EPO-induced phosphorylation of ERK1/2 and JNK in mammary carcinoma cells expressing EPOR-R129C. R3230-GFP cells
transfected with empty pCR3.1 vector or EPOR-R129C were either left untreated as controls (C) or incubated with the indicated concentration of rEPO
for 10 minutes. Whole cell lysates were analyzed by Western blotting using antibodies against phosphorylated or total proteins to detect (A) JAK2,
JAK1 and STAT-5, (B) ERK1/2, and (C) JNK. Representative blots are shown. The phosphorylated (P) and total (T) proteins are indicated by the arrows.
Comparable sample loading and protein integrity were confirmed by stripping the blots and hybridizing to respective antibodies to detect total
protein amounts in the samples. The relative positions of the molecular weight markers are indicated in each blot. Quantitative representation of
phosphorylated proteins using densitometry normalized to total protein levels are shown below the blots for ERK1/2 and JNK (n= 3 independent
experiments using 3 different single cell clones, (*P,0.05).
doi:10.1371/journal.pone.0000549.g006
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skin-fold window chamber angiogenesis model, we focused on
erythropoietin blockade during the initial stages of tumorigenesis
by employing local antagonists targeting erythropoietin function.
Whether systemic treatment with agents targeting erythropoietin,
such as purified R103A-EPO antagonist protein, can produce
regression of high tumor burdens and/or prevent metastasis
remains to be determined. The systemic administration of putative
anti-angiogenic agents targeting erythropoietin and its receptor
may be limited by the development of anemia due to the
suppression of erythropoiesis. Although local erythropoietin
blockade in tumors may represent one approach to overcome this
problem, selective inhibition of EPOR function to specifically
target cancer cells may constitute an alternative future strategy. In
a series of recent studies, erythropoietin has emerged as a major
tissue-protective cytokine against various types of injury in diverse
non-hematopoietic tissues [43–45]. The characterization of EPO
variants that mediate the non-hematopoietic biologic effects of
EPO without inducing signaling in hematopoietic cells [46]
suggests that strategies to develop EPO-EPOR antagonists to
selectively target non-hematopoietic cells- possibly including
cancer cells and tumor vasculature- without causing anemia might
be feasible, particularly when the exact structure of the cell surface
receptor that mediates erythropoietin signaling in non-hemato-
poietic cells is ascertained [47].
MATERIALS AND METHODS
Reagents
Recombinant erythropoietin (Procrit) was purchased from the
outpatient pharmacy at Duke University Medical Center.
Recombinant soluble EPOR (307-ER-050), neutralizing mono-
clonal antibody against EPO (mab287) and murine IgG1 as
negative control antibody (mab002) were from R&D Systems
(Minneapolis, MN) and were reconstituted in phosphate-buffered
saline (PBS). Polyclonal anti-EPO (H-162), anti-EPOR (M-20),
anti-JAK2 (C-20), anti-phospho-JAK2 (Tyr1007/1008), anti-
STAT5 (N-20) antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA). Phospho-ERK1/2 (Thr202/Tyr204), total
ERK1/2, phospho-JNK (Thr183/Tyr185), total JNK, phospho-
Figure 7.Effect of tumor EPOR-R129Cexpression oninvivo ERK1/2 phosphorylation, Ki67proliferationantigen expression,microvessel density and
hypoxia. Sections of pCR3.1 vector control and EPOR-R129C mammary fat pad tumors were analyzed by immunocytochemistry as described in Materials
and Methods. (A–C) Phospho-ERK, (D) Ki67, (E) CD31, and (F) Pimonidazole hypoxia marker. #P,0.0001;*P=0.0006; {P=0.0008; 1 P=0.026.
doi:10.1371/journal.pone.0000549.g007
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from Cell Signaling Technologies (Beverly, MA). The mutant
erythropoietin R103A-EPO antagonist cDNA [48,49] and mam-
malian expression vector (pcDNA3.1) were provided by Dr. H.
Franklin Bunn and Dr. Kevin W. Harris. The constitutively active
mutant EPOR-R129C cDNA [28–31,34–36] was provided by Dr.
Harvey F. Lodish and cloned into pCR3.1 vector (Invitrogen). All
plasmid sequences were confirmed by sequencing at the Duke
University Medical Center DNA sequencing facility using an ABI
PRISM
(TM) 377 DNA sequencer and Dye Terminator Cycle
Sequencing system (Perkin-Elmer).
Cell culture, transfections and in vitro proliferation
assays
R3230 rat mammary carcinoma cells that constitutively express
GFP (R3230-GFP) were maintained in RPMI medium supple-
mented with 10% fetal bovine serum (Hyclone). R3230-GFP cells
sensitive to G418 were transfected with expression plasmids using
Lipofectamine reagent (Invitrogen, Carlsbad, CA) and 48 hours
later, cells were cultured in fresh medium containing 400 mg/ml
G418 (Invitrogen) to select resistant single cell clones isolated in
cloning chambers. Negative controls included mock transfected
cells that underwent 100% cell death in G418. In addition, cells
were transfected with empty expression vectors to isolate single cell
clones of G418-resistant, negative control cell lines. In vitro growth
curves of transfected cell lines were generated by daily counts of
cells plated in triplicates (5610
4 cells/well) in serum-containing
medium in 6-well plates. Culture media was changed every day.
Cells were trypsinized and counted daily using a Coulter Counter.
Cell cycle analysis was performed during exponential growth in
serum-containing medium by propidium iodide staining and
FACS analysis. Cells were trypsinized, fixed with ice-cold ethanol,
and stained with propidium iodide (Sigma) in the presence of
RNAse (Qiagen). Cells were then subjected to flow cytometric
analysis to determine the fractions of cells in subdiploid, G1, S,
and G2/M phase populations. Hematopoietic 32D cells that were
transfected to express EPOR were described previously [50]. To
measure inhibition of EPO-dependent proliferation by protein
antagonists, 32D cells were cultured in phenol-free medium in 96-
well plates (5610
4 cells/well) for 3 days in the presence of
0.3 units/ml of rEPO and increasing concentrations of either
sEPOR or neutralizing anti-EPO mab-287. Cells were incubated
with MTT reagent (dimethylthiazol-2-yl-2,5-diphenyltetrazolium)
for 3 hours at 37uC, solubilized in isopropanol:hydrochloric acid
(24:1) solution and the optical density (562–650 nm) was de-
termined using a microtitre plate reader.
Protein analyses
To prepare whole cell lysates, cells were washed with ice-cold
phosphate-buffered saline and lysed in a buffer containing 1%
Triton-X-100, 10% glycerol, 150 mM NaCl, 20 mM Tris-HCl
(pH 7.4), 5 mM EDTA, supplemented freshly with leupeptin
10 mg/ml, aprotinin 10 mg/ml, pepstatin 1 mg/ml, 1 mM PMSF,
1m MN a 3VO4 and 10 mM NaF. In some experiments, cells were
starved free of serum for one hour and then incubated with rEPO
prior to lysis. The cell lysates were cleared by centrifugation at
16,0006g for 15 minutes and protein concentration in the
supernatants was determined by the Bio-Rad protein assay. The
proteins were denatured at 95uC for 4 minutes in Laemmli sample
buffer and separated by SDS-polyacrylamide gel electrophoresis
(PAGE) using 4–12% Tris-glycine gels (Novex). The separated
proteins were subsequently transferred to Immobilon PVDF
membranes (Millipore), blocked with 5% non-fat milk in TBST
(20 mM Tris-HCl, 137 mM NaCl, 0.1% Tween-20, pH 7.5) for
1 hour and incubated with primary antibodies at 4uC overnight
followed by horseradish peroxidase-conjugated secondary antibo-
dies. Proteins were detected using enhanced chemiluminescence and
bands were visualized by autoradiography. As positive control for
EPOR expression, protein extracts of spleen tissue previously
harvested from phenylhydrazine-treated anemic mice was used
[51]. To detect secreted R103A-EPO in cell culture supernatants,
singlecellclonesofstably transfected R3230-GFPcellswerecultured
in fresh medium for 48 hours and an aliquot of the culture medium
was analyzed directly by SDS-PAGE and immunoblotting.
Animals
Female athymic nude mice (BALB/c nu/nu) 8–10 week old were
obtained from the National Cancer Institute and housed in
a temperature-controlled animal-care barrier facility with a 12-h
light-dark cycle. All procedures were approved by and in
accordance with the guidelines of Duke Institutional Animal Care
and Use Committee and the National Institutes of Health Guide
for the Care and Use of Laboratory Animals (NIH publication
No. 85-13, revised 1996). Animals were treated in a humane
fashion and all efforts were made to minimize animal suffering and
the number of animals used.
Dorsal skin-fold window chambers and tumor cell
injection
Nude mice were anesthetized with a mixture of ketamine
(100 mg/kg, i.p.) and xylazine (10 mg/kg i.p.), and window
chamber surgeries were performed under sterile conditions [2]. A
5 mm diameter flap of skin was dissected away from opposing
surfaces of the dorsal skin fold, leaving a fascial plane with
associated vasculature. The hole was held vertically away from the
body with a titanium saddle that was sutured to both sides of the
flap. Tumor cells (5610
3 cells/10 ml) were injected into the
remaining fascial layer using a Hamilton syringe and glass
windows were attached to the center of the saddle to cover the
surgical site. Treatments were co-injected with the tumor cells
during the surgeries and included recombinant sEPOR (8 mg/
injection) or anti-EPO mab (40 mg/injection) at doses that were
about eight-fold higher than that required to maximally inhibit
EPO-dependent in vitro proliferation of hematopoietic cells (figure
S2). As negative control for these treatments, mouse IgG1 protein
(40 mg/injection) was injected in 4 window chambers and phosphate
buffered saline was injected in 3 windows. In previous studies,
injection of bovine serum albumin had no effect on angiogenesis and
tumor growth [2]. Erythropoietin (280 units/treatment) in a volume
of 7 ml was combined with hydron [poly(2-hydroxyethyl methacry-
late); 12% in ethanol; Sigma], and dried in a desiccator at 4uCt o
form a transparent pellet, which was implanted adjacent to the
tumor cell injection site in the window chamber. The concentrated
form of pharmaceutical grade rEPO (Procrit, 40,000 units/ml)
permitted the maximum administration of 280 units into each
window chamber. The formulation buffer in pellet form was used as
a negative control for erythropoietin treatments and consisted of
100 mM NaCl, 20 mM sodium citrate, 0.3 mM citric acid [pH 6.9]
and 2.5 mg/ml human albumin (Sigma).
Intravital microscopy, tumor growth and
angiogenesis assessments
Window chambers were imaged using a Carl Zeiss MPS intravital
microscope (Carl Zeiss, Hanover, MD) equipped with a color
video camera (Carl Zeiss ZVS-3C75DE) connected to a PC
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Corporation, Frederick, MD). Fluorescence epi-illumination was
provided with a 100 W mercury-arc lamp (AttoArc HBO, Carl
Zeiss, Inc.) and FITC filter (excitation 450–490 nm, emission
520 nm). Images were acquired at low magnification (2.56) and
analyzed using Scion Image software. Measurements were
performed with the investigator blinded to the treatment group.
Tumor area was determined by manually outlining the GFP(+)
area and quantification of the surface area (mm
2) was calculated
using computer imaging software. Tumor-associated vessels were
defined as those present in the GFP(+) tumor area. These vessels
were manually traced by zooming in on the tumor area in the
computer-acquired images and the total length of the blood vessels
in each tumor area was calculated from the tracings using the
computerized imaging software. Vascular length density (VLD)
was calculated by dividing the total tumor-associated vessel length
by the tumor area (mm/mm
2).
Orthotopic tumor growth
Tumor cells (5610
6) were inoculated into the mammary fat pad of
mice. Three independent single cell clones of each stable cell line
were analyzed. Tumor dimensions were measured by caliper twice
a week and tumor volume (mm
3) was estimated using the following
formula:
Volume~length|width|height|p=6
where all linear dimensions are in mm. After the final
measurements, the hypoxia marker pimonidazole hydrochloride
(NPI, Inc. Belmont, MA) was administered at a dose of 70 mg/kg
by i.p. injection one hour prior to sacrifice. The excised tumors
were snap frozen in liquid nitrogen.
Immunocytochemistry
Serial 10 mm sections of frozen mammary fat pad tumor tissues
were used. Four randomly selected tumors from each group
(pCR3.1 vector and EPOR-R129C) were analyzed in a blinded
fashion. Angiogenesis was assessed by microvessel count using
anti-CD31 antibody (Dako, Copenhagen, Denmark) as blood
vessel marker. Sections were incubated with primary antibody
(dilution 1:50) at room temperature for 60 minutes, and slides
were stained by the avidin-biotin method. After the slides were
scanned at low magnification (406), six hot spots (fields with
maximum vessel density) per tumor were selected for vessel count.
The mean value from six fields was recorded as the microvessel
density for each tumor. Staining for the Ki67 proliferation antigen
was determined using anti-Ki67 rabbit monoclonal antibody
(NCL Ki67, Novocastra, Newcastle, UK) applied overnight at 4uC
(dilution 1:400). Nuclear staining of tumor cells was considered
positive for Ki-67. After the slides were scanned at low
magnification, the cells with positively stained nuclei were counted
in six microscopic fields in each tumor and the Ki67 index was
calculated as the ratio of Ki67 positive nuclei per total nuclei.
Phospho-ERK1/2 (Thr202/Tyr204) staining was performed using
a polyclonal antibody (Cell Signaling Technologies) applied
overnight at 4uC (dilution 1:200). Staining was evaluated at low
magnification (206) by acquiring digital images from 4 or 5
representative phospho-ERK+ fields in each tumor and the extent
of staining was quantified for each tumor in a blinded fashion as
the percentage of positively stained tumor cells/total tumor cells.
Hypoxic tumor areas were determined by immunostaining with
monoclonal antibody against pimonidazole adducts (Hypoxyp-
robe, Chemicon, dilution 1:50). Digital image analyses were
performed under low magnification (46) to calculate the
percentage of pimonidazole positive area /total tumor area by
acquiring images of four randomly chosen fields in each tumor.
Statistical analyses
Data and group measures are reported as mean6s.e.m. The effect
of treatments and differences between multiple experimental
groups were assessed using repeated measures analysis of variance
(ANOVA) and Bonferroni multiple comparisons post-hoc test.
The differences between two experimental groups were de-
termined using Student’s t-tests. The level of statistical significance
was P,0.05.
SUPPORTING INFORMATION
Figure S1 (A) Expression of EPOR-R129C in R3230-GFP cells.
Whole cell lysates of R3230-GFP cells transfected with empty
vector or EPOR-R129C expression vector were analyzed by
Western blotting. Lane 1. Mouse spleen control; Lanes 2–4.
Vector-transfected single cell clones; Lanes 5–7. EPOR-R129C-
transfected single cell clones. Molecular weight marker is in-
dicated. Arrow indicates ,66 kDa immunoreactivity consistent
with the molecular weight of EPOR. (B) Proliferation of
transfected R3230-GFP cells in vitro. Growth curves for EPOR-
R129C, R103A-EPO, and empty vector (pcDNA3.1 or pCR3.1)
transfected R3230-GFP mammary carcinoma cells were generated
by daily cell counts in triplicates (n=3 experiments in each group).
(C) Cell cycle profile of transfected R3230-GFP cells. R3230-GFP
cells transfected with EPOR-R129C, R103A-EPO or empty
expression vectors were labeled with propidium iodide and the
percentage of subdiploid, G1, S, and G2/M populations were
determined by flow cytometry. (n=3 experiments in each
group).
Found at: doi:10.1371/journal.pone.0000549.s001 (0.90 MB TIF)
Figure S2 Soluble EPOR and neutralizing anti-EPO mono-
clonal antibody (mab) inhibit EPO-dependent proliferation of
hematopoietic cells.- Erythropoietin-dependent 32D cells were
cultured in the presence of recombinant EPO and the indicated
concentrations of (A) sEPOR or (B) anti-EPO neutralizing
mab (mab287). MTT assays were performed and proliferation
plotted as a percentage of maximum in the absence of the
inhibitor.
Found at: doi:10.1371/journal.pone.0000549.s002 (0.60 MB TIF)
Figure S3 (A) Expression of erythropoietin R103A-EPO antag-
onist in R3230-GFP cells. Cell culture supernatants were analyzed
by immunoblotting using anti-EPO polyclonal antibody. Lane 1.
Negative control untransfected (UT) R3230-GFP cell supernatant;
Lanes 2–4. Empty pcDNA3.1 vector-transfected single cell clones
as negative controls; Lanes 5–7.-Single cell clones expressing
R103A-EPO in culture supernatants. Molecular weight markers
are indicated. Arrow indicates ,34 kDa immunoreactivity
consistent with the molecular weight of EPO and demonstrating
the secretion of R103A-EPO into the culture medium. (B) rEPO-
induced phosphorylation of ERK1/2 in cells expressing R103A-
EPO antagonist. R3230-GFP cells transfected with empty
pcDNA3.1 vector or R103A-EPO antagonist were either left
untreated as controls (C) or treated with indicated concentration of
rEPO for 10 minutes. Whole cell lysates were analyzed by
Western blotting using antibodies to detect phospho-ERK1/2
(top panel). The same proteins separated in a duplicate gel
demonstrate comparable amount of total ERK1/2 protein
(bottom panel).
Found at: doi:10.1371/journal.pone.0000549.s003 (0.44 MB TIF)
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